

**Capricorn Venture Partners makes first investment from its
Capricorn Sustainable Chemistry Fund
and completes ViroVet's series A funding**

ViroVet: an animal health company focused on combatting viral infections in livestock

LEUVEN, Belgium, 6 October 2017 — Capricorn Venture Partners is pleased to announce the first investment for its Capricorn Sustainable Chemistry Fund (CSCF). The fund has invested in ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock. This investment concludes the second closing of ViroVet's series A financing round, in which they raised another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

ViroVet pioneers in developing novel and innovative vaccines based on a unique proprietary technology platform that has the potential to produce vaccines faster and more cost-effectively. These vaccines are tailor-made to maximize efficacy and minimize safety concerns. In addition, the vaccines are thermostable thereby removing any cold-chain requirement. Earlier this year, ViroVet and GALVmed entered into a collaboration to develop novel vaccines for sheep and goats. The company also develops fast-acting antiviral drugs that are critical to the effective control and treatment of respiratory diseases of cattle and swine, thereby reducing secondary bacterial infections and the associated use of antibiotics.

The objective of the Capricorn Sustainable Chemistry Fund is to create shareholder value through financial return combined with the Sustainability Impact of the planned investments. The ViroVet investment contributes to realising the United Nation's Sustainable Development Goals, in particular Goal nrs. 2 and 3, which concern zero hunger and good health and wellbeing. Over 70 percent of human diseases originate in animals, so healthy animals contribute to healthy people and sustainable food production. In this context, ViroVet vaccines contribute to improving animal health by making animal production more efficient and sustainable, and in preventing and controlling diseases which threaten animal production, public health and trade.

Erwin Blomsma, PhD, co-founder and CEO of ViroVet stated that *"We are excited that Capricorn Venture Partners came on board. With the second closing of our series A investment round, we are able to reach important milestones and to show the animal health sector that there are better ways to treat as well as prevent viral disease outbreaks in livestock."*

Ludwig Goris, Investment Manager at Capricorn Venture Partners, added: *"We are very excited to announce ViroVet as the first investment out of our Capricorn Sustainable Chemistry Fund. We have been following the company for some time and believe strongly in the disruptive market potential of its innovative anti-viral and vaccine technology. We are convinced that the team of Erwin, Nesy, Stefaan and their colleagues will be very successful and we are happy to join a strong consortium of investors"*

About ViroVet

ViroVet is a biopharmaceutical company with a clear objective to develop innovative technologies to improve the health and value of livestock. The company is headquartered in Heverlee near Leuven, Belgium and continues to build on the livestock assets and know-how that it has accumulated since 2008 while adding new products, including vaccines, to the pipeline.

PMV (via Biotech Fund Flanders), Agri Investment Fund, Gemma Frisius Fund, Vives Louvain Technology Fund and Capricorn Sustainable Chemistry Fund participated in ViroVet's series A round.

About Capricorn

Capricorn Venture Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Venture Partners is managing the venture capital funds Capricorn Sustainable Chemistry Fund, Capricorn ICT Fund, Capricorn Health-tech Fund and Capricorn Cleantech Fund. In addition, it is the management company of Quest for Growth, quoted on NYSE Euronext Brussels, and the investment manager of Quest Cleantech Fund, sub-fund of Quest Management SICAV (www.capricorn.be).

For more information

Dr Jos B. Peeters,
Chairman Executive Committee
Capricorn Venture Partners NV
Lei 19/1 - B-3000 Leuven
(Belgium)
Tel: +32(0)16 28 41 00
jos@capricorn.be